No Data
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
Prelude Therapeutics Price Target Announced at $5.00/Share by HC Wainwright & Co.
Express News | Prelude Therapeutics Inc : H.c. Wainwright Raises to Buy From Neutral
H.C. Wainwright Upgrades Prelude Therapeutics(PRLD.US) to Buy Rating, Maintains Target Price $5
KIVA SALES LEADER JOINS PRELUDE TO ACCELERATE EXPANSION ACROSS THE CANNABIS SUPPLY CHAIN
Prelude Therapeutics (PRLD) Gets a Sell From Barclays